Insulet (PODD)
(Delayed Data from NSDQ)
$229.94 USD
-0.05 (-0.02%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $229.85 -0.09 (-0.04%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$229.94 USD
-0.05 (-0.02%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $229.85 -0.09 (-0.04%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth C Momentum C VGM
Zacks News
Here's Why You Should Retain Henry Schein (HSIC) Stock for Now
by Zacks Equity Research
Favorable Dental business trends and expansion efforts through acquisitions and partnerships bode well for Henry Schein (HSIC).
Labcorp (LH) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Labcorp (LH) is anticipated to drive growth in the first quarter of 2024 through base business expansion, integrating acquisitions and partnerships and advancing in science and technology.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Quest Diagnostics (DGX) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Acquisitions and partnerships with health plans are expected to drive Quest Diagnostics' (DGX) base business performance in the first quarter of 2024.
Will Insulet (PODD) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Insulet (PODD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Insulet (PODD) Stock Moves -0.34%: What You Should Know
by Zacks Equity Research
Insulet (PODD) concluded the recent trading session at $177.41, signifying a -0.34% move from its prior day's close.
Neogen (NEOG) Q3 Earnings Miss Estimates, Gross Margin Expands
by Zacks Equity Research
Neogen's (NEOG) third-quarter fiscal 2024 results reflect solid core revenue growth in both segments.
Encompass Health (EHC) Plans a 50-Bed Facility to Serve Texas
by Zacks Equity Research
Encompass Health (EHC) unveils plans to build an inpatient rehabilitation hospital in San Antonio to bring improved health outcomes and further fortify its presence in Texas.
Here's Why Insulet (PODD) is a Strong Growth Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
5 Medical Product Stocks to Buy Amid Industry Challenges
by Indrajit Bandyopadhyay
Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. SYK, RMD, ZBH, PODD and LNTH are well-poised to gain from the favorable factors.
Acadia (ACHC) Buys CTCs to Boost Care Access in North Carolina
by Zacks Equity Research
Acadia Healthcare (ACHC) acquires three CTCs in the Raleigh, Greenville and Hillsborough regions of North Carolina, therefore increasing its CTC nationwide footprint and fetching improved revenues.
Wall Street Analysts See a 38.87% Upside in Insulet (PODD): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 38.9% upside potential for Insulet (PODD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
5 Stocks to Buy on the Dip to Gain From the Wall Street Rally
by Nalak Das
We have narrowed our search to five large-cap stocks with attractive valuations. These are TWLO, ZS, NEE, AWK and PODD.
3 Strong Stocks Down at Least 30% to Buy Now
by Benjamin Rains
Three S&P 500 stocks worth considering as buy-and-hold investments that are down at least 30% from their highs even as the market trades at records.
Here's Why You Should Buy Insulet (PODD) Stock Right Now
by Zacks Equity Research
Investors remain confident in the Insulet (PODD) stock due to the huge success of Omnipod 5.
Why Insulet (PODD) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Boston Scientific (BSX) Grows IC Business With New FDA Nod
by Zacks Equity Research
The AGENT DCB of Boston Scientific (BSX) is already available in Europe, parts of Asia Pacific and Latin America.
ICON (ICLR) Gains From Strategic Deals, New Innovations
by Zacks Equity Research
ICON (ICLR) continues to evolve its collaboration and delivery models, invest in technology, and enhance its project and program management capabilities.
Quest Diagnostics (DGX) Hurt by Lower Testing Sales, Competition
by Zacks Equity Research
Quest Diagnostics (DGX) faces intense competition, primarily from LabCorp as well as other commercial laboratories and hospitals.
Bruker (BRKR) Inks Definitive Agreement to Acquire ELITechGroup
by Zacks Equity Research
Bruker (BRKR) announces a share purchase agreement to acquire the molecular diagnostics innovator ELITechGroup.
Insulet (PODD) Q4 Earnings, Revenues Top Mark, Margins Expand
by Zacks Equity Research
In the fourth quarter, Insulet (PODD) achieves the milestone of 425,000 estimated active global customers using Omnipod products.
Alcon (ALC) Faces Rising Expenses, Tough Competitive Scenario
by Zacks Equity Research
In the surgical business, Alcon (ALC) faces a mix of competitors, ranging from large manufacturers with multiple business lines to small manufacturers.
Quanterix (QTRX) Expands in Alzheimer's Testing With Alliances
by Zacks Equity Research
Quanterix's (QTRX) blood-based biomarker testing offers a superior alternative, aligning with the recommendations of the NIA-AA criteria for AD diagnosis.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Down -15.31% in 4 Weeks, Here's Why You Should You Buy the Dip in Insulet (PODD)
by Zacks Equity Research
Insulet (PODD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.